web analytics
12.6 C
Sunday, May 29, 2022

What Happened to Ibio Inc (NYSEMKT:IBIO)

Ibio Inc (NYSEMKT:IBIO) continues to make higher highs and higher lows since reversing off $0.50 lows in February.

The stock made a spectacular move up in October of last year after IBIO offered to assist the U.S. government by making its proprietary antibody production technology available to deal with the current Ebola virus outbreak. In response to shareholder and media inquiries, the company said the way it produces, in collaboration with Caliber Biotherapeutics, pharmaceutical proteins in plants has proven to have efficacy advantages over similar antibodies produced in Chinese hamster ovary cells. The stock has roughly quadrupled year to date through Wednesday, as the Ebola virus outbreak spread. On Thursday, an Air France aircraft flying from Paris was grounded in Madrid amid concerns one of the passengers onboard had Ebola.

In recent news IBIO announced the issue of a new U.S. patent expanding the company’s iBioModulator(TM) thermostable immunomodulator protein portfolio. The new patent, serial number 9,012,199, is entitled “Recombinant Carrier Molecule for Expression, Delivery, and Purification of Target Polypeptides.” The fundamental composition of matter claims grant iBio important exclusivity over new, modified carrier molecules derived from the company’s proprietary iBioModulator(TM) thermostable immunomodulator protein system and their use with one or more target proteins or antigens.

Ibio Inc (NYSEMKT:IBIO) is developing a proprietary product, IBIO-CFB03, for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases using its iBioLaunch(TM) platform. The company also offers proprietary products and product licenses to others, based on its proprietary iBioLaunch and iBioModulator(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.

To Find out the inside Scoop on IBIO Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect.

On October 16 IBIO confirmed, in response to shareholder and media inquiries: (i) the applicability of its issued U.S. iBioLaunch(TM) platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus, and (ii) that iBio has an ongoing relationship with Caliber Biotherapeutics LLC reflected by a License and Collaboration Agreement dated February 14, 2013 pursuant to which iBio and Caliber have been collaborating on commercial opportunities for recombinant antibodies and antibody-related proteins based on the speed, efficiency, and cost advantages of producing pharmaceutical proteins in plants instead of with bioreactor-based manufacturing methods.

Based on published scientific data, the superior homogeneity of antibody glysolylation (the addition of sugars to proteins) in plants can provide significant efficacy advantages over similar antibodies produced in Chinese hamster ovary (CHO) cells.

We Have a MASSIVE Stock Pick Coming ASAP. Only a Crazy Person would Miss this!

Sign Up now for our 100% FREE Penny Stock Newsletter

Confirmed reports coming from a number of investors in the know suggest that IBIO is NOT in fact the manufacture partner to the government. In any case this stock is currently receiving massive publicity and could easily continue on way higher from here.

Currently trading at a $66 million market valuation IBIO continues to sit at the top of many speculators watch lists. The stock has been highly successful in attracting a loyal shareholder base who believes this one goes higher. We will be updating IBIO as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with IBIO.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in IBIO either long or short and we have not been compensated for this article.

More articles


Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.